{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-26-000128","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2026-10-15T12:46:40+00:00","discovered_at":"2026-10-15T12:50:00.337109+00:00","generated_at":"2026-10-15T12:50:23.266617+00:00","sec_items":["1.01","2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Recursion prices $200M equity offering, reports Sanofi option milestone and early clinical data","bullets":["Recursion priced 61,540,000 Class A shares at $3.25/share for ~$200M gross proceeds; offering expected to close Oct 16, 2026.","Preliminary Sept 30, 2026 cash, equivalents and restricted cash ~$561M, including ~$86M net ATM proceeds from 23,696,330 shares; runway into 2029.","Sanofi optioned first collaboration development candidate; triggered $10M milestone, bringing total payments to $144M; Recursion eligible for >$300M more and low double-digit royalties.","REC-4881 TUPELO Phase 1b/2: 87% of 16 efficacy-evaluable FAP patients had polyp burden reductions, 47% median reduction at week 13; no Grade 4/5 TRAEs.","REC-1245 DAHLIA Phase 1: 91.7% (11/12) at 45/65 mg achieved disease control at 8 weeks; 45 mg selected for expansion after 65 mg exceeded MTD."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-26-000128","json":"https://secwatch.observer/filing/0001601830-26-000128.json","markdown":"https://secwatch.observer/filing/0001601830-26-000128.md","text":"https://secwatch.observer/filing/0001601830-26-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/0001601830-26-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/rxrx-20261015.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-15T12:50:23.266617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}